03:35 AM EDT, 10/26/2026 (MT Newswires) -- GSK's (GSK.L) investigational B7-H4-targeted antibody-drug conjugate mocertatug rezetecan showed clinically meaningful and durable responses in a phase 1 trial involving patients with platinum-resistant ovarian cancer. Updated data from the global phase I Behold-1 trial showed that Mo-Rez achieved a confirmed objective response rate of 62%, a median duration of response of 12.2 months, and median progression-free survival of 11.1 months after more than 13 months of follow-up, the British drugmaker said Monday. Behold-1 is a two-part, open-label, phase 1 study including 136 platinum-resistant ovarian cancer, or PROC, patients.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.